{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T01:47:20Z","timestamp":1771724840747,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012297","name":"Society of Family Planning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012297","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.contraception.2019.06.002","type":"journal-article","created":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T11:02:09Z","timestamp":1560164529000},"page":"283-287","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Effects of ritonavir-boosted protease inhibitors on combined oral contraceptive pharmacokinetics and pharmacodynamics in HIV-positive women"],"prefix":"10.1016","volume":"100","author":[{"given":"Teresa","family":"Barcellos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Natavio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank Z.","family":"Stanczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dandan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J.","family":"Jusko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole M.","family":"Bender","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2019.06.002_bb0005","series-title":"The joint United Nations programme on HIV\/AIDS. wwwunaidsorg. Accessed on","author":"17","year":"2018"},{"key":"10.1016\/j.contraception.2019.06.002_bb0010","article-title":"Estimated HIV incidence and prevalence in the United States, 2010\u20132015","volume":"23","author":"Prevention","year":"2018","journal-title":"HIV Surveillance Supplemental Report"},{"key":"10.1016\/j.contraception.2019.06.002_bb0015","unstructured":"Centers for Disease Control and Prevention. US medical eligibility criteria for contraceptive use. 2016;MMWR:1\u2013108."},{"key":"10.1016\/j.contraception.2019.06.002_bb0020","series-title":"Clinical pharmacology","article-title":"Department of Health and Human Services Food and Drug Administration. Guidance for industry drug interaction studies \u2014 study design data analysis and implications for dosing and labeling","author":"U.S","year":"2006"},{"key":"10.1016\/j.contraception.2019.06.002_bb0025","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.contraception.2010.04.016","article-title":"Metabolism and pharmacokinetics of contraceptive steroids in obese women: a review","volume":"82","author":"Edelman","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2019.06.002_bb0030","first-page":"133","article-title":"Pharmacokinetics of ethynyloestradiol in humans","volume":"4","author":"Fotherby","year":"1982","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"10.1016\/j.contraception.2019.06.002_bb0035","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s00228-014-1711-0","article-title":"Pharmacokinetic and pharmacodynamic interactions between the hepatitis C virus protease inhibitor, boceprevir, and the oral contraceptive ethinyl estradiol\/norethindrone","volume":"70","author":"Lin","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.contraception.2019.06.002_bb0040","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1177\/0091270011419855","article-title":"The pharmacokinetic interaction between an oral contraceptive containing ethinyl estradiol and norethindrone and the HCV protease inhibitor telaprevir","volume":"52","author":"Garg","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.contraception.2019.06.002_bb0045","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.clinthera.2011.08.012","article-title":"Effect of vicriviroc with or without ritonavir on oral contraceptive pharmacokinetics: a randomized, open-label, parallel-group, fixed-sequence crossover trial in healthy women","volume":"33","author":"Kasserra","year":"2011","journal-title":"Clin Ther"},{"key":"10.1016\/j.contraception.2019.06.002_bb0050","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3851\/IMP1724","article-title":"The effect of atazanavir\/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women","volume":"16","author":"Zhang","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1016\/j.contraception.2019.06.002_bb0055","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/QAI.0b013e3181eb5ff5","article-title":"Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188","volume":"55","author":"Vogler","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.contraception.2019.06.002_bb0060","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1177\/135965350801300415","article-title":"Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women","volume":"13","author":"Sekar","year":"2008","journal-title":"Antivir Ther"},{"key":"10.1016\/j.contraception.2019.06.002_bb0065","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1365-2125.1998.00749.x","article-title":"Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers","volume":"46","author":"Ouellet","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.contraception.2019.06.002_bb0070","unstructured":"Bristol-Meyers Squibb P, NJ. Reyataz (atazanavir): US prescribing information 2009."},{"key":"10.1016\/j.contraception.2019.06.002_bb0075","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/00042560-200204150-00007","article-title":"Pharmacokinetic interaction between nevirapine and ethinyl estradiol\/norethindrone when administered concurrently to HIV-infected women","volume":"29","author":"Mildvan","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.contraception.2019.06.002_bb0080","unstructured":"Merck & Co I, Whitehouse Station, NJ. VICTRELIS\u2122 (boceprivir) capsules: US prescribing information 2011."},{"key":"10.1016\/j.contraception.2019.06.002_bb0085","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1097\/QAI.0b013e31822b8bf8","article-title":"Pharmacokinetics and pharmacodynamics of a combined oral contraceptive and a generic combined formulation antiretroviral in Malawi","volume":"58","author":"Stuart","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.contraception.2019.06.002_bb0090","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/QAI.0b013e3182a9b3f1","article-title":"Effect of protease inhibitors on steady-state pharmacokinetics of oral norethindrone contraception in HIV-infected women","volume":"65","author":"Atrio","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.contraception.2019.06.002_bb0095","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.contraception.2012.12.015","article-title":"Types of combined oral contraceptives used by US women","volume":"88","author":"Creinin","year":"2013","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2019.06.002_bb0100","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1517\/17425255.2013.772579","article-title":"Drug interactions between antiretrovirals and hormonal contraceptives","volume":"9","author":"Tseng","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.contraception.2019.06.002_bb0105","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.contraception.2009.04.011","article-title":"Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic\u2013pituitary\u2013ovarian activity","volume":"80","author":"Edelman","year":"2009","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2019.06.002_bb0110","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.contraception.2012.10.008","article-title":"Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users","volume":"87","author":"Edelman","year":"2013","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2019.06.002_bb0115","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.contraception.2010.01.016","article-title":"Pharmacokinetics of a combined oral contraceptive in obese and normal weight women","volume":"81","author":"Westhoff","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2019.06.002_bb0120","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/cts.12499","article-title":"Role of CYP3A in oral contraceptives clearance","volume":"11","author":"Zhang","year":"2018","journal-title":"Clin Transl Sci"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001078241930201X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001078241930201X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T20:14:17Z","timestamp":1757880857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001078241930201X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S001078241930201X"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2019.06.002","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of ritonavir-boosted protease inhibitors on combined oral contraceptive pharmacokinetics and pharmacodynamics in HIV-positive women","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2019.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}